All In Biotech

Drug Trial Radar · NCT01447862

Vernakalant Versus Ibutilide In Recent-Onset Atrial Fibrillation

Last checked: Nov 19, 2026Latest source record: May 13, 2015 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingRandomized with 101 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

101

Actual

Start

Oct 2011

Primary completion

May 2015

Study completion May 2015

Sponsor

Lead sponsor
Medical University of ViennaAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Oct 6, 2011

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
Who can join
All sexes, from 18 years, up to 90 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Atrial fibrillation is the most common cardiac arrhythmia and is expected to affect about 30 million North Americans and Europeans by 2050. Atrial fibrillation is associated with increased cardiovascular morbidity and mortality, with stroke being an especially important and potentially devastating complication. Many studies have investigated the efficacy of different drugs in converting atrial fibrillation to sinus rhythm. There are numerous randomized controlled trials that have tested the efficacy of agents against placebo and some trials that directly compared the efficacy of two or more different drugs. The class III antiarrhythmic drug Ibutilde is approved for the acute termination of atrial fibrillation and atrial flutter of recent onset and has been shown to be superior to sotalol and equivalent to flecainide in this indication. Recently, the relatively atrial selective antiarrhythmic agent vernakalant has been approved by the European Commission for the rapid conversion of recent onset AF to sinus rhythm in adults. The investigators hypothesize that the period of time needed for cardioversion to sinus rhythm and the efficacy of cardioversion within 90 minutes is different between vernakalant and ibutilide in patients with recent-onset atrial fibrillation.

Conditions

  • Atrial Fibrillation

Interventions

  • Brinavess (Vernakalant)Drug

    3mg/kg Brinavess (Vernakalant) in 100ml normal saline over 10min. If atrial fibrillation continues after another 15 minutes of observation, patients will receive a second infusion of 2mg/kg Brinavess (Vernakalant) over 10 minutes

  • Corvert (Ibutilide)Drug

    Patients will be given 1mg of Corvert (Ibutilide) in 100ml normal saline intravenously over 10min. If atrial fibrillation continues after another 10 minutes of observation, patients will receive a second infusion of 1mg ibutilide over 10min.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Time in minutes until conversion to sinus rhythm (measured from the start of the first study drug administration)Time frame: 90 minutes

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Medical University of Vienna, Department of Emergency Medicine

    Vienna, State of Vienna, Austria

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.